1. Scrip
  2. >>Business

News In Brief: Sotyktu Phase III Win, Novo’s Alhemo Approval, Axsome Agitation Data, Pfizer Gives Back Sangamo Gene Therapy

Humanigen Indictment; WuXi Sells Cell And Gene Business

 
• By Mandy Jackson, Jessica Merrill, and Mary Jo Laffler

BMS's Sotyktu succeeded in two Phase III psoriatic arthritis trials, Novo's Alhemo (concizumab) was approved in the US for hemophilia A and B with inhibitors, Pfizer returned a hemophilia gene therapy to Sangamo ahead of US and EU filings, and more late December news.

Novo had a hemophilia drug approval, while Pfizer gave back rights to a hemophilia A gene therapy (Shutterstock)

Bristol Myers Squibb reported positive topline results from two Phase III clinical trials of its TYK2 inhibitor Sotyktu (deucravacitinib) in psoriatic arthritis (PsA) on 23 December. The POETYK PsA-1 and POETYK PsA-2 trials met their primary endpoints, showing that a significantly greater proportion of Sotyktu-treated patients than those treated with placebo achieved ACR20 response – at least a 20% improvement in the signs and symptoms of PsA – after 16 weeks of treatment.

Sotyktu was approved in the US in September 2022 to treat psoriasis. BMS reported positive topline Phase II results for the oral drug in PsA in November 2020, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.